TrialNature medicine2025

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

Iain B McInnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.